Boston Trust Walden Corp Acquires 268,966 Shares of The Clorox Company (NYSE:CLX)

Boston Trust Walden Corp boosted its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 5,442.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 273,908 shares of the company's stock after purchasing an additional 268,966 shares during the period. Boston Trust Walden Corp owned about 0.22% of Clorox worth $44,622,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of CLX. First Foundation Advisors acquired a new position in Clorox during the first quarter worth $31,000. Innealta Capital LLC bought a new position in shares of Clorox in the 2nd quarter valued at about $30,000. Trifecta Capital Advisors LLC increased its position in shares of Clorox by 139.8% in the second quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company's stock valued at $30,000 after acquiring an additional 130 shares during the last quarter. Quarry LP raised its holdings in Clorox by 99.1% during the second quarter. Quarry LP now owns 229 shares of the company's stock worth $31,000 after acquiring an additional 114 shares in the last quarter. Finally, Family Firm Inc. acquired a new position in Clorox during the second quarter valued at approximately $31,000. 78.53% of the stock is currently owned by institutional investors.

Clorox Stock Performance

Shares of Clorox stock traded down $2.29 during trading on Friday, reaching $156.69. The company's stock had a trading volume of 1,040,134 shares, compared to its average volume of 1,223,216. The company has a quick ratio of 0.63, a current ratio of 1.03 and a debt-to-equity ratio of 5.04. The business's 50-day moving average price is $160.74 and its 200-day moving average price is $145.62. The Clorox Company has a 52 week low of $114.68 and a 52 week high of $169.09. The firm has a market cap of $19.46 billion, a PE ratio of 81.19, a P/E/G ratio of 3.19 and a beta of 0.41.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported $1.82 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.28. Clorox had a net margin of 3.95% and a return on equity of 281.12%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.97 billion. Equities analysts forecast that The Clorox Company will post 6.64 earnings per share for the current year.

Clorox Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, November 7th. Shareholders of record on Wednesday, October 23rd will be paid a dividend of $1.22 per share. The ex-dividend date of this dividend is Wednesday, October 23rd. This represents a $4.88 dividend on an annualized basis and a yield of 3.11%. Clorox's dividend payout ratio (DPR) is presently 252.85%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CLX shares. JPMorgan Chase & Co. boosted their price target on Clorox from $148.00 to $174.00 and gave the stock a "neutral" rating in a research report on Friday, October 11th. BNP Paribas upgraded shares of Clorox to a "strong sell" rating in a research note on Friday, September 6th. Citigroup boosted their price objective on shares of Clorox from $165.00 to $170.00 and gave the stock a "neutral" rating in a research note on Friday, September 6th. Jefferies Financial Group upgraded shares of Clorox from a "hold" rating to a "buy" rating and raised their target price for the company from $174.00 to $187.00 in a research note on Tuesday, October 1st. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Clorox from $144.00 to $151.00 and gave the stock a "hold" rating in a research report on Friday, August 2nd. Six analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $150.14.

Insider Buying and Selling at Clorox

In other news, EVP Angela C. Hilt sold 1,733 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $165.52, for a total transaction of $286,846.16. Following the sale, the executive vice president now directly owns 13,471 shares of the company's stock, valued at approximately $2,229,719.92. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.51% of the company's stock.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.